GlassScriptPhysician profile
Jonathan P Nieves
NPI 1851702674
$39,947.73
in general payments reported to CMS, 2019-2025
32 companies · $7,112 in 2025
The $7,112 reported for 2025 was more than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,667 · 2020: $15K · 2021: $1,064 · 2022: $5,432 · 2023: $5,682 · 2024: $4,333 · 2025: $7,112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Travel and Lodging: $1,949.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,177.53 |
| Travel and Lodging | $1,948.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $13,778.38 | 2019-2020 | |
| Abbott Laboratories | $12,290.78 | 2019-2025 | Aveir, Ensite, Gallant |
| Medtronic, INC. | $4,472.16 | 2021-2025 | Cobalt Dr Mri Surescan, Micra, Evera Mri Xt Dr Surescan |
| Boston Scientific Corporation | $2,985.66 | 2022-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor, Resonate El Icd Vr |
| Impulse Dynamics (USA) INC. | $1,428.52 | 2022-2025 | Optimizer |
| Biosense Webster, INC. | $1,321.37 | 2022-2025 | Carto 3 |
| Cardiva Medical, INC. | $651.39 | 2022-2025 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs, Cardiva Vascade Mvp Xl Vvcs 10-12f |
| Atricure, INC. | $495.92 | 2022-2024 | |
| Biotronik INC. | $362.80 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $223.20 | 2022-2025 | Camzyos, Eliquis |
| Astellas Pharma US INC | $214.99 | 2019 | |
| Janssen Pharmaceuticals, INC | $209.55 | 2022-2024 | Xarelto |
| Pfizer INC. | $169.30 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.71 | 2019 | |
| Ekos Corporation | $134.61 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elutia, INC. | $130.18 | 2024-2025 | Ecm Patch,Pouch |
| Amgen INC. | $118.18 | 2020 | |
| Cvrx, INC. | $115.66 | 2024-2025 | Barostim Neo System |
| Abiomed | $114.58 | 2025 | |
| Edwards Lifesciences Corporation | $113.82 | 2019 | |
| Kestra Medical Technology Services, INC. | $108.61 | 2023-2024 | Assure Wcd |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $91.12 | 2024-2025 | Lifevest |
| Cardinal Health 200 LLC | $48.03 | 2019 | |
| Novartis Pharmaceuticals Corporation | $42.62 | 2025 | |
| Ethicon US, LLC | $33.65 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $30.86 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $30.64 | 2024 | |
| Acutus Medical, INC. | $24.78 | 2022 | |
| Vital Connect, INC | $22.65 | 2024 | Vitalpatch Rtm |
| Astrazeneca Pharmaceuticals LP | $17.98 | 2019 | |
| Philips North America LLC | $16.45 | 2022 | |
| Medline Industries LP | $14.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Nieves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.